BGB-16673 is an investigational chimeric degradation activating compound (CDAC) targeting BTK. Watch the mechanism of action video (MoA) to learn more.

Watch this video to understand the mode of action of Chimeric Degradation Activating Compounds (CDAC), a new investigational targeted approach for hematologic malignancies.

Join Dr. Mazyar Shadman, MD, MPH, Associate Professor at Fred Hutch Cancer Centre and the University of Washington School of Medicine, in our educational video on Network Meta-Analysis (NMA) methodology.

Join Dr. Mazyar Shadman, MD, MPH, Associate Professor at Fred Hutch Cancer Centre and the University of Washington School of Medicine, in our educational video on Matching Adjusted Indirect Comparison (MAIC) methodology.

Overview of current and future therapeutic options for the management of patients with B-cell lymphomas presented at ISHL13.